Two Questions: Who is dave and who is Imran Khan? Imran Khan acquires 2.5% of Dave's Class A Common stock » 16:38 DAVE
We Got the news I have been waiting for.... not sure how this turns out. I was expecting big things... Marqeta announces four year extension to Cash App contract » 16:18 MQ, SQ
TOAST rebound. Guess who's on Fast Midday Show today Toast raises FY23 revenue view to $3.81B-$3.87B consensus $3.78B » 16:13 TOST Prior gu
Ok first thoughts. I am nervous I didn't get Disney upgrades today./ Very nervous. If you followed me in yesterday be aware of that./ Confident of my chart read that we are at support but really no idea how bad that devil Gov of Fla has made things for them and really.. a coin toss here. I was sure we would get at least two upgrades today the actual day of earn.. maybe it's a weird quiet period... ?
23andMe, Inc. Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health reports. 23andMe also has the largest crowdsourced platform for advanced genetic research, which enables the Company to deliver ongoing genetic reports, new health features and new risk predictions to customers annually. The platform also accelerates the identification of novel drug discovery programs rooted in human genetics across a spectrum of disease areas. 23andMe’s platform was built to help people access, understand, and benefit from the human genome. “The Company made solid progress this past quarter across both our Therapeutics and Consumer businesses,” said Anne Wojcicki, Co-Founder and CEO of 23andMe. “We exited the exclusive drug discovery phase of our GSK collaboration in a strong position to capitalize on new partnerships and opportunities to work with a number of biotech companies on genetics-based drug discovery. ---> I think I remember Van owns alot of this stock. This sounds like good news.
JUST SOME HOUSEKEEPING.- This thread I believe by far has the most winners as related to pages! When I do all the math it's going to be incredible the marketing we can do with this. I don't think we should keep rambling on. Let me get that 10th 40% winner and bam! I'm closing the window. I really detest these super long threads. And I get bad feedback from the Hf community who don't like toggling to page 770 for an idea. So I go to Charleston on the 18th. I really hope we can END this thread at that time. It's going to be a very frustrating Zig Zag market till the end of year and we are going to get one of those famous sell off this month into Sept. I have been part of many of these Price based sell offs and indeed started many of these, but one thing you have to know from an old pro-- at some point everyone at the same time says.. ah F it it's been a great year lets just book it!<---- And that moment is close.~stoney
MQ was $5.60 Aug 1 with the overhang of maybe losing most all of their rev if their deal with Square expired. THIS IS NO SURGE!!! And I am torn between buying more to prove a point or turning tail and running... Not sure what to do. This should be up North of 30%!!!! Marqeta Stock Surges as Block Contract Renewal Removes ‘Major Overhang’ Marqeta Stock Surges as Block Contract Renewal Removes ‘Major Overhang’ Wed, August 9, 2023, 8:00 AM EDT In this article: MQ -1.00% Shares of Marqeta soared Wednesday after the digital payment technology company announced it had renewed its contract with Block to power its Cash App debit card. Marqeta (ticker: MQ) stock jumped 20% in premarket trading Wednesday to $5.96.